Table 1.
Clinicopathological significance of p16 expression
| Factors | Weak p16 expression (%) | p Value |
| Sex | ||
| Male | 48% | χ2 test: p=0.604 |
| Female | 44% | |
| Age | ||
| Mean age weak p16 expression: 64 years | t test: p=0.236 | |
| Mean age strong p16 expression: 62 years | ||
| Grade | ||
| Well | 50% | Spearman: p=0.501 |
| Moderate | 47% | |
| Poor | 42% | |
| Sites | ||
| Oral cavity | 15% | χ2 test: p<0.001 |
| Pharynx | 25% | |
| Larynx | 63% | |
| Stage | ||
| I | 35% | Spearman: p=0.210 |
| II | 47% | |
| III | 43% | |
| IV | 51% | |
| T stage | ||
| 1 | 34% | Spearman: p=0.043 |
| 2 | 35% | |
| 3 | 55% | |
| 4 | 52% | |
| N stage | ||
| 0 | 52% | Spearman: p=0.213 |
| 1 | 21% | |
| 2 | 54% | |
| 3 | 33% | |
| Previous radiotherapy | ||
| No | 35% | χ2 test: p<0.001 |
| Yes | 61% | |
| Recurrence | ||
| No | 41% | χ2 test: p=0.706 |
| Yes | 46% | |